CompletedPhase 4

Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection

France460 participantsStarted 2018-10-10

Plain-language summary

Chlamydia trachomatis is the most commonly reported bacterial sexually transmitted infection (STI), especially among young women. Up to 75% of C. trachomatis infected women are asymptomatic. If untreated, C. trachomatis infection can cause sequelae such as pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility. C. trachomatis can also cause anorectal infections, which are typically asymptomatic. Among women with urogenital chlamydial infection, around 36-91% also had concurrent anorectal chlamydial. Notably, there was no association with anal intercourse in the studies that reported it. However, guidelines do not recommend routine anorectal testing, but restricted testing in people who are in high-risk groups, report anal sexual behavior, or have anal symptoms, i.e., on selective indications. This is in contrast to urogenital testing, which is a routine procedure in STI care services. The anal transmission of C. trachomatis in women may occur by autoinoculation from the vagina due to the close proximity of the vagina and the anus. C. trachomatis could lead to a persistent infection in the lower gastrointestinal tract, suggesting the potential role of autoinoculation of cervical chlamydial infection from the rectal site. Such (repeat) urogenital infections could lead to reproductive tract morbidity. Recommended treatments for C. trachomatis infections are a single 1g dose of azithromycin or 100mg of doxycycline 2 times a day for 7 days. Although these two regimens are equivalent for urogenital infection, no study has compared the effectiveness of these two treatments on anorectal infection. If rectal C. trachomatis is a hidden reservoir influencing transmission rates, and considering the potential complications of cervical infections, providing further evidence of the need for effective rectal treatments among women is highly relevant.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female * Age \> 18 years * Negative β-hCG urinary assay and efficacious contraception for participant consulting in specialist centre * Participant requesting an abortion at a pregnancy termination centre and efficacious contraception after abortion * C. trachomatis-positive test for vaginal specimen using a Nucleic Acid Amplification Test (NAAT) * Sexually active * Consultation in one of the participating centers * Agree to be contacted for follow-up * Member or beneficiary of a social security system * Free written informed consent signed by the participant and the investigator (no later than the inclusion day and before performing any examination required for the study) Exclusion Criteria: * Women who have symptoms suggesting pelvic inflammatory disease (PID) * Receipt of an antibiotic with antichlamydial activity within 21 days before screening or between screening and enrollment * Contraindications to tetracyclines, macrolides or ketolids (including allergy and treatment with colchicine, cisapride, ergot alkaloids and retinoids) * Inability to swallow pills * Refusal to participate in the study * Objectives of the study not understood. * Breast-feeding * Patients with serious cardiac diseases: documented prolongation of the QT tract of the ECG, cardiac arrhythmias, advanced heart failure (classification New York Heart Association or NYHA \>III) * Patients treated with anticoagulants or drug with a definite potential of "Torsades de Pointe" or pro…

What they're measuring

Nucleic Acid Amplification Assay result

Timeframe: 6 weeks

Trial details

NCT IDNCT03532464

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-08-17